Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

    Results show prolonged courses of stable disease and excellent
    tolerability and indicate potential for use as combination treatment for
    cancer

QUEBEC CITY, Sept. 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer. Under the supervision of lead investigator, Daniel D. Von Hoff, MD, Senior Investigator and Physician in Chief at the Translational Genomics Research Institute in Scottsdale, Arizona, this open-label, dose-escalation, multi-center, intermittent treatment Phase 1 trial was conducted at 2 clinical sites in Scottsdale: the Mayo Clinic with principal investigator Donald W. Northfelt, MD, and at Premiere Oncology with principal investigator David Mendelson, MD.

Results

The study was performed in two parts and included 42 patients overall. In Part I, 22 patients were studied on doses ranging from 13 to 800 mg/week. In Part II, the weekly dose was split into 3 doses taken 8 hours apart, and ultimately, 20 patients received doses from 120 to 600 mg/week. Stable disease with time to failure ranging from 20 to 60+ weeks was achieved in 12 patients with various cancer types, including melanoma and cancers of the colon/rectum, lung, pancreas, prostate, tongue, trachea and thyroid. In several of these patients, the duration of stabilization exceeded the duration of disease control on previous treatment regimens. Except for a dose-limiting gastrointestinal reaction in a patient with pre-existing GI problems, no clinically relevant drug-related adverse events or changes in laboratory safety parameters were observed.

"Prolonged courses of stable disease with minimal to no toxicity are encouraging signs", said Dr. Von Hoff. "The applications for an oral agent with these mechanisms of action are numerous."

Paul Blake, MD, AEterna Zentaris Senior Vice President and Chief Medical Officer added, "We are pleased with these Phase 1 results on AEZS-112, which indicate the potential for safe combination with other anticancer drugs. We now look forward to working on the further development of AEZS-112 in collaboration with our expert investigators."

About the AEZS-112 Phase 1 Study

This open-label, dose-escalation, multi-center, intermittent treatment Phase 1 study included patients with advanced solid tumors and lymphoma who had either failed standard therapy or for whom no standard therapy existed. Patients received a once-a-week oral administration of AEZS-112 for three consecutive weeks, followed by a one-week period without treatment. The cycles were repeated every four weeks based on tolerability and response, basically planned for up to four cycles, but allowing for continuation in case of potential benefit for the patient. The starting dose of AEZS-112 in this study was 13 mg/week, with doubling of doses in subsequent cohorts in the absence of significant toxicity. Primary endpoints of the Phase 1 trial focused on determining the safety and tolerability of AEZS-112 (maximum tolerated dose, MTD), as well as establishing a recommended Phase 2 dose and regimen. Secondary endpoints aimed at establishing the pharmacokinetics and determining the efficacy based on standard response criteria.

Preliminary results from this study were presented recently at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado. Poster #5567 entitled, "Phase I dose-escalation, safety, and pharmacokinetic study on weekly oral AEZS-112, a small molecule anti-cancer agent in patients with advanced cancer and lymphoma", was presented by D. W. Northfelt, M.D.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Surface Plasmon Resonance (SPR) is ... optical phenomenon that is sensitive to changes in the dielectric properties of the medium ... changes in refractive index occurring up to 300 nm above the metal surface (Au) ...
(Date:2/28/2017)... 2017  Phosphorus, a computational genomics and clinical ... the Phosphorus Scientific Advisory Board, an established group ... the company on the development of new products ... visit http://phosphorus.com/about-us/ to learn more about ... gathered some of the top leaders in the ...
(Date:2/28/2017)... 28, 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases ... fourth quarter and full year ended December 31, ... recent business and clinical highlights. "During ... development pipeline by starting five clinical trials across ...
(Date:2/28/2017)... MA (PRWEB) , ... February 28, 2017 , ... ... clinical trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel ... celebrating 15 years of meeting this unique need within the biotechnology and pharmaceutical ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):